Crinetics' New Pill Shows Promise for Treating Acromegaly, Send Stock Soaring 63%

Crinetics' pill paltusotine succeeded in acromegaly study, sending biotech stock soaring 63%
Paltusotine switched acromegaly patients from shots to a daily pill while maintaining hormone control
CEO says positive data shows Crinetics has strong clinical development and reinforces pill as preferred option
Paltusotine was well tolerated with mostly mild side effects vs placebo patients
Results bode well for upcoming 2nd late-stage study of paltusotine in acromegaly patients in 2023

investors.com

Relevant topic timeline:

9/29/2023

Small biotech's obesity pill shows promise, sending stock soaring

Structure Therapeutics' stock rises as its obesity pill shows potential to challenge pharmaceutical giants like Lilly and Novo in the market for new obesity medicines.